Diazepam KLH Conjugate

• Efficient Antibody Generation: Covalent linkage of diazepam to KLH promotes robust immunogenicity for the development of high-affinity polyclonal and monoclonal antibodies.
• Preservation of Epitope Integrity: Conjugation strategies maintain the native structural features of diazepam, ensuring selective and specific antibody responses.
• Assay Development Compatibility: Suitable for use in competitive ELISA, lateral flow assays, and other immunoanalytical methods targeting benzodiazepines.
• Research and Diagnostic Utility: Enables sensitive detection of diazepam in biological samples for pharmacokinetic, forensic, and clinical toxicology applications.

Diazepam KLH conjugate consists of diazepam covalently linked to keyhole limpet hemocyanin (KLH), a high-molecular-weight, immunogenic carrier protein commonly used for hapten immunogen preparation. The conjugation is performed via established coupling chemistries that preserve the structural integrity of the diazepam moiety while maximizing epitope availability for immune recognition. This conjugate is specifically designed for the generation of anti-diazepam polyclonal and monoclonal antibodies, as well as for use in the development of competitive immunoassays. Diazepam, a benzodiazepine that acts as a positive allosteric modulator of GABA_A receptors, is widely studied for its pharmacological effects, including anxiolytic, sedative, muscle relaxant, and anticonvulsant activities. The diazepam-KLH conjugate enables sensitive and specific detection of diazepam and related compounds in biological matrices. It is suitable for applications in pharmacokinetic studies, forensic toxicology, therapeutic drug monitoring, and the development of diagnostic assays.